09-01-2020

IRE ELiT and Telix Pharmaceuticals enter French Distribution Agreement for Prostate Cancer Imaging

IRE ELiT and Telix Pharmaceuticals enter French Distribution Agreement for Prostate Cancer Imaging

We are proud to announce today that we have signed a distribution agreement with Advanced Nuclear Medicine Ingredient S.A., a subsidiary of Telix Pharmaceuticlas Limited, for the distribution of the metastatic prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical cold kit complementary of its GalliAd 68Ge/68Ga new generation generator, specifically designed for cold kits preparation.

Under the terms of the agreement, IRE ELiT has been designated as the exclusive distributor of the TLX591-CDx in France and the French overseas territories, both during the initial period of Temporary Operating Authorization  and after the granting of a Marketing Authorization (MA) on the European market in 2021.

To date, TLX591-CDx does not have a marketing authorization.


Press release available here.

IRE Elit - Environement and lifescience Technology